FDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer
Aug 05, 2026
View online
FDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer
AstraZeneca-Bristol Myers Merger Denied: What It Exposed
Andrea Necchi: A Combined Analysis of PURE01 and SURE02
FDA Grants Breakthrough Therapy Designation to Olomorasib for KRAS G12C-Mutant Advanced Pancreatic Cancer
Wee Joo Chng: Asia Can Become a Global Epicenter for Clinical Trials
Alejandra Mendez: The Doctor Behind the Powerful Story of Patient Number 8
How cancer is making a difference in a key election race in Iowa
VIRO 2026 – Global Voices in Renal Oncology
Horizon Europe Earlier and More Precise Palliative Care Grant 2026
Robert L. Fine Cancer Research Foundation Research Grant 2026
2026 Hereditary Cancer Genetics: Incorporation into Clinical Care
Louisiana Oncology Society 2026 Cancer Congress
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
